source
- RNAi developers see surge in IPOs and funding as industry interest revivesBioPharma Dive’s latest data‑visualization series highlights a rapid rise in interest and investment for companies developing RNA interference (RNAi) medicines. After a years‑long lull, more than…
- Star raises $200 million after successful spinouts of Electra and Vega TherapeuticsStar, a biopharma company, announced it has secured $200 million in new funding. The capital follows the recent exits of its subsidiaries Electra Therapeutics and Vega Therapeutics, which were spu…